APYX - Apyx Medical GAAP EPS of -$0.17 misses by $0.03 revenue of $12.61M misses by $0.43M
2023-03-16 07:03:55 ET
- Apyx Medical press release ( NASDAQ: APYX ): Q4 GAAP EPS of -$0.17 misses by $0.03 .
- Revenue of $12.61M (-25.0% Y/Y) misses by $0.43M .
- Advanced Energy revenue of $10.5 million, down 30% year-over-year.
- OEM revenue of $2.1 million, up 15% year-over-year.
-
Full Year 2023 Financial Outlook:
The Company is introducing financial guidance for the year ending December 31, 2023 to:
- Total revenue in the range of $58.0 million to $61.0 million vs. $52.16M consensus, representing growth of approximately 30% to 37% year-over-year, compared to total revenue of $44.5 million for the year ended December 31, 2022.
- Total revenue guidance assumes:
- Advanced Energy revenue in the range of $50.0 million to $53.0 million, representing growth of approximately 36% to 44% year-over-year, compared to Advanced Energy revenue of $36.8 million for the year ended December 31, 2022.
- OEM revenue of approximately $8 million, representing growth of approximately 4% year-over-year, compared to $7.7 million for the year ended December 31, 2022.
- Total revenue guidance assumes:
- Net loss attributable to stockholders of approximately $14.0 million, compared to $23.2 million for the year ended December 31, 2022.
- Total revenue in the range of $58.0 million to $61.0 million vs. $52.16M consensus, representing growth of approximately 30% to 37% year-over-year, compared to total revenue of $44.5 million for the year ended December 31, 2022.
For further details see:
Apyx Medical GAAP EPS of -$0.17 misses by $0.03, revenue of $12.61M misses by $0.43M